Key Points
- Director Simon Read sold 2,778 DNTH shares for approximately $326,554 at an average price of $117.55, reducing his direct ownership by 50%. He also sold 2,777 shares earlier in August for about $304,220.
- Dianthus Therapeutics shares opened at $113.70 after falling 1.6%, while the company recently reported a quarterly EPS loss of $0.90—worse than the $0.85 analyst estimate—despite revenue exceeding expectations.
- Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $124.27; Wedbush recently raised its target to $122. Institutional investors own 47.53% of the stock.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) Director Simon Read sold 2,778 shares of Dianthus Therapeutics stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total transaction of $326,553.90. Following the transaction, the director directly owned 2,778 shares in the company, valued at approximately $326,553.90. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Simon Read also recently made the following trade(s):
- On Monday, August 10th, Simon Read sold 2,777 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $109.55, for a total transaction of $304,220.35.
Dianthus Therapeutics Trading Down 1.6%
DNTH stock opened at $113.70 on Thursday. The business's 50-day moving average price is $99.51 and its two-hundred day moving average price is $84.41. The firm has a market cap of $6.22 billion, a PE ratio of -27.40 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 1-year low of $22.06 and a 1-year high of $117.88.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.
Institutional Trading of Dianthus Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after purchasing an additional 618 shares in the last quarter. American Century Companies Inc. increased its stake in Dianthus Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company's stock valued at $1,009,000 after buying an additional 6,323 shares during the last quarter. Invesco Ltd. lifted its position in Dianthus Therapeutics by 31.1% during the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company's stock worth $390,000 after buying an additional 4,962 shares in the last quarter. Alliancebernstein L.P. lifted its position in Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock worth $21,887,000 after buying an additional 149,200 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $27,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several analysts have commented on DNTH shares. Wedbush raised their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. TD Cowen restated a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Guggenheim reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wolfe Research reiterated an "outperform" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $124.27.
Read Our Latest Research Report on DNTH
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
